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Abstract
Introduction: Despite the success of interventional processes such as drug-eluting stents, complete
prevention of restenosis is still hindered by impaired or delayed endothelialization or both. Here, we report
that 1H-pyrrole-2,5-dione-based small molecule-generated mesenchymal stem cell-derived functional endothelial cells
(MDFECs) facilitated rapid transmural coverage of injured blood vessels.
Methods: Small molecules that induced CD31 expression were screened by principal component analysis (PCA). Rat
mesenchymal stem cells (MSCs) were treated with selected small molecules for up to 16 days, and the expression
levels of CD90 and CD31 were examined by immunocytochemistry. In vitro functional assays of MDFECs, including
tube formation assays and nitric oxide production assays, were performed. After MDFECs (intravenous, 3×106 cells per
animal) were injected into balloon-injured rats, neointima formation was monitored for up to 21 days. The endothelial
coverage of denuded blood vessels was evaluated by Evans Blue staining. The functionality of repaired blood vessels
was evaluated by measuring vasorelaxation and hemodynamic changes. Additionally, derivatives of the selected small
molecules were examined for their ability to induce endothelial markers.
Results: PCA indicated that 3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione effectively induced
MDFECs. MDFECs inhibited the neointima formation of denuded blood vessels by facilitating more rapid
endothelialization. Further examination indicated that derivatives with a 1H-pyrrole-2,5-dione moiety are important for
initiating the endothelial cell differentiation of MSCs.
Conclusions: Small molecules with 1H-pyrrole-2,5-dione as a core structure have great potential to improve the
efficacy of MSC-based cell therapy for vascular diseases, such as atherosclerosis and restenosis.
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Introduction
Restenosis refers to the recurrence of blood vessel nar-
rowing due to neointima formation, which is character-
ized by uncontrolled proliferation of vascular smooth
muscle cells (VSMCs) [1]. Although the introduction of
innovative approaches, such as the drug-eluting stent,
has significantly reduced the rate of restenosis [2],
complete prevention of restenosis is still not achievable
with frequent late stent thrombosis due to impaired or
delayed endothelialization or both [3]. The importance
of a functional endothelium in preventing intimal thick-
ening and vascular thrombosis has long been recognized
[4–6]. Therefore, finding a way to achieve rapid and suf-
ficient transmural coverage with a functional endothelial
layer may further improve the outcomes of current
interventional approaches for managing atherosclerosis.
During the last decade, MSCs have been the major type
of stem cells for therapy because of their self-renewal and
multilineage differentiation ability [7], relatively easy isola-
tion protocol from abundant sources [8–10], and low im-
munogenicity [11, 12]. These characteristics make MSCs
the most commonly used stem cells in numerous clinical
studies [13]. Previous studies have investigated the feasi-
bility of differentiating MSCs into endothelial cells (ECs)
and demonstrated that MSC-derived ECs have the charac-
teristics and functions of ECs. Nevertheless, most of those
studies focused on in vitro validation of EC-like character-
istics [14, 15] or angiogenic or vasculogenic potential or
both [16, 17] rather than in vivo functionality, such as
the endothelialization of denuded blood vessels in ani-
mal models. The concept of changing the fate of stem
cells by using small molecules was introduced about a
decade ago [18], and our group has empirically demon-
strated that it is possible to direct cell fate by using vari-
ous small molecules [19–21].
In this report, we describe the generation of MSC-
derived functional ECs (MDFECs) that achieve rapid
transmural coverage of injured blood vessels by using 3-
(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyr-
role-2,5-dione. Further experimental data suggested that
the derivatives of this molecule with 1H-pyrrole-2,5-
dione as a core moiety have a great potential to improve
the efficacy of MSC-based cell therapy for vascular dis-
eases, such as atherosclerosis and restenosis.
Methods
Principal component analysis
Principal component analysis (PCA) was conducted on
the basis of numerical values derived from the sandwich
enzyme-linked immunosorbent assay (ELISA). We scaled
the two sets of the coordinates to plot them together on
the map. The three largest principal components of the
PCA analysis are PC1, PC2, and PC3. The detailed proce-
dures were performed as previously described [19].
Sandwich enzyme-linked immunosorbent assay
Polyvinylchloride microtiter high-binding plates (96-well)
were coated overnight with 100 ng of the capture antibody
at 4 °C. The plates were washed with phosphate-buffered
saline (PBS), and we inhibited the capture antibody with
5 % bovine serum albumin (BSA) in PBS at room
temperature, overnight. After the plate was washed with
PBS, 5 μg of cell lysate was added to each well with
blocking buffer, and the plate was incubated for 90 min
at 37 °C. The plate was washed with PBS containing
0.02 % Tween-20 (0.02 % PBS-T). After the detector
antibody was added, the plate was incubated for 2 h at
room temperature in a humid atmosphere and was
washed with 0.02 % PBS-T. Next, the plate was incu-
bated again with a peroxidase-conjugated secondary
antibody with 3 % BSA for 90 min at 37 °C and then
washed with 0.02 % PBS-T. Finally, 100 μl of tetra-
methylbenzidine solution (Sigma-Aldrich, St. Louis,
MO, USA) was added as a substrate. After 10 min, 25 μl
of 0.1 M sulfuric acid was added to stop the reaction,
and the absorbance was measured immediately at 450
nm on an ELISA plate reader (Bio-Rad Laboratories,
Hercules, CA, USA).
Animals
Four- and eight-week-old Sprague–Dawley rats were
used for MSC isolation and the vascular injury model,
respectively. Before the experimental procedure, the rats
were anesthetized with zoletil (20 mg/kg) and xylazine
(5 mg/kg). All animal experimental procedures were ap-
proved by the Institutional Animal Care and Use Com-
mittee of Yonsei University College of Medicine in
cooperation with the Association for Assessment and
Accreditation of Laboratory Animal Care and performed
in accordance with the Guidelines and Regulations for
Animal Care.
Isolation and culture of rat MSCs
Bone marrow-derived MSCs were isolated and collected
from aspirates of rat femurs and tibias with 10 ml of
MSC medium consisting of Dulbecco’s modified Eagle’s
medium (DMEM)-low glucose supplemented with 10 %
fetal bovine serum (FBS) (Invitrogen) and 1 % antibiotic-
penicillin and streptomycin. Mononuclear cells that had
been recovered from the interface of Ficoll-Paque PLUS
(GE Healthcare, Little Chalfont, UK)-separated bone
marrow were washed twice and resuspended in DMEM
with 10 % FBS and then plated at a density of 1×106 cells
per 100-mm dish. The cultures were maintained at 37 °C
in a humidified atmosphere containing 5 % CO2. After
72 h, the non-adherent cells were discarded, and the ad-
herent cells were thoroughly washed twice with PBS.
Fresh MesenPRO RS™ Medium (Invitrogen) was added
and then replaced every 3 days for approximately 10 days
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to achieve stable multi-potentiality. The characterization
of the MSCs isolated by using our in-house protocol has
been previously described [22], and additional experi-
ments for evaluating the differentiation potential of the
MSCs used in the present study confirmed their osteo-
genic and adipogenic differentiation potential (Additional
file 1: Figure S1).
In vitro differentiation assay
Isolated MSCs were subjected to differentiation assays
by using the rat MSC functional identification kit
(SC020; R&D Systems, Minneapolis, MN, USA) in ac-
cordance with the protocols of the manufacturer.
Treatment of small molecules
At passage 1 or 2, MSCs were seeded in 60-mm dishes
at 1×105 cells/ml and treated with a final concentration
of 1 μM of small molecules, including SB216763 (EMD
Millipore, Billerica, MA, USA) and SB derivatives
(Sigma-Aldrich; Santa Cruz Biotechnology, Dallas, TX,
USA; and JINC). The media (DMEM with 10 % FBS)
were replaced with fresh small molecule-containing
media every 3 days for 16 days.
Reverse transcription-polymerase chain reaction analysis
The expression levels of various genes were analyzed
by reverse transcription-polymerase chain reaction
(RT-PCR). Total RNA was prepared by using the
UltraspectTM-II RNA system (Biotecx Laboratories,
Inc., Houston, TX, USA), and single-stranded cDNA
was then synthesized from the isolated total RNA by
using avian myeloblastosis virus (AMV) reverse transcript-
ase. A 20-μl reverse transcription reaction mixture con-
taining 1 μl of total RNA, 1X reverse transcription buffer
(10 mM Tris–HCl, pH 9.0, 50 mM KCl, and 0.1 % Triton
X-100), 1 mM deoxynucleoside triphosphates (dNTPs)
0.5 units of RNase inhibitor, 0.5 μg of oligo(dT)15, and
15 units of AMV reverse transcriptase was incubated at
42 °C for 15 min, heated to 99 °C for 5 min, and then in-
cubated at 4 °C for 5 min. PCR was performed for 35 cy-
cles with 3′ and 5′ primers based on the sequences of
various genes. The primers are listed in the Additional
file 2: Table S1.
Immunocytochemistry
Cells were grown on four-well plastic dishes. After incu-
bation, the cells were washed twice with PBS and then
fixed with 4 % paraformaldehyde in PBS for 30 min at
room temperature. The cells were washed again with PBS
and then permeabilized for 30 min in PBS containing 0.2
% Triton. Next, the cells were blocked in PBS containing
10 % goat serum and incubated for 1 h with CD90, CD31,
vascular endothelial growth factor (VEGF) receptor 1
(Flk-1), β-catenin (Santa Cruz Biotechnology, 1:200),
and acetylated α-tubulin (Abcam, Cambridge, MA,
USA, 1:200). The cells were washed again three times
for 10 min with PBS and incubated with a FITC (fluor-
escein isothiocyanate)-conjugated secondary antibody
(Jackson ImmunoResearch Laboratories, Inc., West
Grove, PA, USA, 1:500) for 1 h. Finally, the cells were
treated with DAPI (4′,6-diamidino-2-phenylindole)
(Sigma-Aldrich) to stain nuclei for 2 min and then
mounted on slides. Photographs of the cells were ac-
quired by using an immunofluorescence microscope
(Carl Zeiss, Oberkochen, Germany, LSM700). All im-
ages were acquired by using an excitation filter with a
reflected light fluorescence microscope and transferred
to a computer equipped with ZEN software (Carl Zeiss).
Lipid uptake assay using DiI-LDL
A lipid uptake assay using DiI-LDL (3,3′-dioctadecylin-
docarbocyanine-low density lipoprotein) was conducted.
The cells were incubated with DiI-LDL (10 μg/ml) for 4
h at 37 °C. The cells were lysed in 0.1 N NaOH and 0.1
% SDS and shaken for 10 min followed by fluorescence
reading for DiI-LDL (excitation/emission at 530/580
nm). The fluorescence of DiI-LDL was normalized by
the cell lysate protein concentrations as previously de-
scribed [23].
Nitric oxide production assay
In brief, the cells were washed with warm PBS and stim-
ulated with 5 μM acetylcholine (ACh) in phenol red-free
DMEM for 60 min. The media were collected and spun
at 2000g for 1 min before being transferred to a new
tube and subjected to a nitric oxide (NO) production
assay. We followed the protocol included with the NO
release Fluorometric Assay Kit (BioVision, Milpitas, CA,
USA).
Fluorescence in situ hybridization analysis
Arterial sections (3 μm) were mounted on gelatin-coated
glass slides to ensure different stains. After de-paraf-
finization and re-hydration, we used STAR*FISH© Rat 12/
Y Paints (Cambio,) as described in the protocol of the
manufacturer.
Evans Blue staining and morphometric analysis
Femoral vein injections with 5 % Evans Blue dye (Sigma-
Aldrich) were performed 60 min before sacrifice to
analyze the denuded and recovered areas. The harvested
common carotid artery was fixed with 10 % formalin,
paraffin-sectioned cross-sectionally, and stained with
hematoxylin and eosin. Re-endothelialization and the in-
tima/media area were measured by using ImageJ soft-
ware (National Institutes of Health, Bethesda, MD,
USA).
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Vascular injury and cell injection
A 2-Fr Fogarty arterial embolectomy catheter (Edwards
Lifesciences, Irvine, CA, USA) was inserted in the left
common carotid artery of the rats. The balloon was in-
flated in the common carotid artery and moved back
and forth three times for endothelial denudation. For the
delivery of MSCs treated with SB for 16 days, 3×106 cells
in 0.3 ml of saline were injected per animal via intraven-
ous (i.v.) injection in the femoral vein. For the MSC con-
trol group, MSCs without SB treatment were delivered
(3×106 cells per 0.3 ml saline, per animal) via i.v. injec-
tion through the femoral vein. Animals were sacrificed
3, 5, 7, 14, and 21 days after the balloon injury (BI) for
further analysis. The in vivo studies were conducted by
using three independent animals (rather than three ani-
mals of one cohort).
Aortic ring preparation and vasodilator responsiveness
After anesthesia, the common carotid arteries were ex-
cised and placed in HEPES-Tyrode’s solution (10 mM
glucose, 10 mM HEPES, 134 mM NaCl, 5.6 mM KCl, 1
mM MgCl2, and 2.5 mM CaCl2), which was aerated with
100 % O2. The arteries were prepared as ring segments
(3 mm in length). Each artery ring was mounted hori-
zontally between two parallel stainless steel hooks in a
temperature-controlled 3-ml organ bath. One hook was
fixed, whereas the other was connected to a force trans-
ducer (UFER; Kishimoto Medical Instruments, Kyoto,
Japan) to measure isometric contraction. After an equili-
bration period of 30 min at 37 °C in HEPES-Tyrode’s so-
lution aerated continuously by 100 % O2, the ring
segments were stretched passively by imposing an opti-
mal resisting force of 10 mN, which was found to be the
optimal force for use with the 70 mM high K+ HEPES-
Tyrode’s solution (K+ substitution for Na+). The arterial
rings were repeatedly contracted with 70 mM high K+
HEPES-Tyrode’s solution until stable responses were ob-
tained. Submaximal contraction was elicited by 50 mM
high K+ HEPES-Tyrode’s (50 K) solution. Endothelial-
dependent vasodilation was induced by the addition of
progressive doses of ACh (Sigma-Aldrich; 10−8-10−4 M).
In vivo blood flow measurement
After the rats were anesthetized, a small incision was
carefully made in the throat area to isolate the left com-
mon carotid artery. A transit time perivascular flow
meter (T402; Transonic System Inc., Ithaca, NY, USA)
and a transonic flow probe (1.0PRB4284) were used to
measure the blood flow. The equipment was calibrated
by using a standard flow meter in milliliters per minute.
The waveform of the blood flow was recorded for 10
min and analyzed by using LabChart 7 software
(ADInstruments, Dunedin, New Zealand).
Western blot
Western blot was performed by using primary antibodies
against phosphorylated glycogen synthase kinase 3 beta
(GSK3β) at Ser9, phosphorylated β-catenin, and β-actin
(Santa Cruz Biotechnology, 1:1000).
In vitro angiogenesis
Analysis of capillary formation was performed using an
in vitro angiogenesis kit (Chemicon International Inc.,
Billerica, MA, USA) in accordance with the instructions
of the manufacturer. A gel matrix solution (50 μl) was
applied to each well of a 96-well plate, which was incu-
bated for 1 h at 37 °C. The cells were then trypsinized
and resuspended at a density of 5×103 cells in 50 μl of
DMEM with or without VEGF (20 nM), plated on the
gel matrix, and incubated for 24 h. The total length of
the formed tube was calculated by using the ImageJ pro-
gram from three independent experiments.
Scanning electron microscopy
After fixation with glutaraldehyde, the slides were
washed for 5 min in malonic sodium phosphate buffer
(pH 7.3). The specimens were fixed in 1 % osmium tet-
roxide for 2 h at 4 °C. The samples were separately
washed for 5 min in water, 50 % ethanol, and 70 % etha-
nol; for 15 min in 95 % ethanol; and two times for 15
min each in absolute ethanol. An SEM S-800 (Hitachi,
Tokyo, Japan) was used with magnifications of 10 to
10,000.
Statistical analysis
Quantitative data are expressed as the mean ± standard
deviation of at least three independent experiments. For
statistical analysis, one-way analysis of variance with
Bonferroni correction was performed by using OriginPro
8 SR4 software (version 8.0951; OriginLab Corporation,
Northampton, MA, USA). Data normality was tested by
Shapiro-Wilk test. A P value of less than 0.05 was con-
sidered statistically significant.
Results and Discussion
In a preliminary screening to identify small molecules
that induce the EC differentiation of MSCs, we treated
MSCs with commercially available small-molecule inhib-
itors of six different groups of the protein kinase super-
family—kinase group AGC (protein kinase A (PKA),
protein kinase C (PKC), and protein kinase G (PKG)),
CaM (calcium/calmodulin-dependent protein kinase),
CK1 (casein kinase 1 group), kinase group CMGC (cyc-
lin-dependent kinase (CDK), mitogen-activated protein
kinase (MAPK), GSK3, and CDC-like kinase (CLK kin-
ase)), TK (tyrosine kinase), and TKL (tyrosine-kinase like
group) kinase—every 3 days (each, 1 μM) for up to 16
days and evaluated the differentiation status by sandwich
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Fig. 1 (See legend on next page.)
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ELISA for the endothelial marker CD31. Subsequent
PCA on the profile matrix for the cross-relationship be-
tween specific cell types and small molecules indicated
that 3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-
1H-pyrrole-2,5-dione, known as SB216763 (SB), was a
hit compound that induces the EC differentiation of
MSCs (Additional file 3: Figure S2). Furthermore, com-
pared with untreated MSCs, SB-treated MSCs expressed
higher levels of CD34 and von Willebrand Factor (vWF)
(Additional file 4: Figure S3). Although SB induced the
expression of EC markers, such as CD31 and vWF, this
induction does not necessarily guarantee that those cells
possess EC-related functionality. Therefore, we con-
ducted additional tests, including tests to assess the EC
functionality of SB-treated cells, and we refer to those
cells as induced MDFECs (iMDFECs).
Morphological examination revealed that, although the
iMDFECs did not show drastic morphological changes
(Additional file 5: Figure S4A), they had a time-
dependent decrease in the mRNA expression of the
MSC marker CD71 (Additional file 5: Figure S4B) and
an increase in CD31 mRNA expression (Additional file
5: Figure S4C). Immunocytochemical staining for CD90
and CD31 also indicated that the CD31 expression in
iMDFECs increased but that the expression of the MSC
marker CD90 decreased with time (Fig. 1a). Further-
more, the iMDFECs showed increased expression levels
of other EC markers, such as CD34, endothelial nitric
oxide synthase (eNOS), vascular endothelial cadherin
(VE-cadherin), vascular cell adhesion molecule 1
(VCAM-1), and Flk-1 (Fig. 1b and c). Because adhesion
molecules, such as VE-cadherin and VCAM-1, are im-
portant players in mediating EC adhesion and the subse-
quent blood vessel maturation [24, 25], the increased
expression levels of these molecules are expected to play
a crucial role in the initial settlement of iMDFECs in
damaged blood vessels in the case of systemic infusion
for therapeutic purposes (i.e., re-endothelialization of de-
nuded blood vessels). Additionally, when stimulated with
VEGF (20 nM), iMDFECs showed a trend of increased
total tube length compared with that of the control
MSCs, suggesting that the iMDFECs were responsive
to angiogenic growth factor (Fig. 1d). Furthermore,
compared with control MSCs, iMDFECs produced a
higher amount of NO (71.50±4.55 vs. 101.75±5.63) in
response to ACh (Fig. 1e), which is known to induce
NO release from ECs [26]. A lipid uptake assay using
DiI-LDL indicated increased lipid uptake by iMDFECs
compared with that of untreated MSCs (Additional
file 6: Figure S5).
To assess the feasibility of using iMDFECs in thera-
peutic approaches and to evaluate in vivo functionality,
we systemically transplanted control MSCs or iMDFECs
in vascularly injured animals via i.v. injection (3×106
cells per 0.3 ml of saline, per animal) through the fem-
oral vein. We used male rats and female rats as the
source of MSCs and for the vascular injured animal
model, respectively. Thus, we could track the transplanted
cells by detecting Y chromosomes. Immunohistochemical
staining of the carotid artery for Y chromosomes demon-
strated that some of the infused iMDFECs resided in the
innermost layer of the carotid artery, suggesting that
iMDFECs physically contributed to the formation of a
functional endothelial layer (Fig. 2a). The relative
amount of cells incorporated into the injured blood ves-
sel was higher in the iMDFEC-transplanted group than
in the MSC-transplanted control group (Additional file 7:
Figure S6).
The results of Evans Blue staining to evaluate the per-
meability of the carotid artery indicated that, although
there was no significant difference in the transluminal
coverage among the groups after 3 weeks (BI vs. BI +
MSC vs. BI + iMDFEC group, 89.59±2.66 vs. 83.87±4.26
vs. 92.47±1.47, respectively), the iMDFEC-transplanted
group showed a rapid increase in the dye-impermeable
area during the first week after vascular injury compared
with that of other groups (79.04±1.95 vs. the BI and BI +
MSC group values of 41.31±1.75 and 43.86±2.34, re-
spectively) (Fig. 2b and Additional file 8: Figure S7). The
Evans Blue-impermeable area of the BI + iMDFEC group
was significantly higher than those of the BI and BI + MSC
groups from day 3 to 14 (Additional file 9: Figure S8A),
suggesting that relatively faster re-endothelialization oc-
curred with iMDFEC transplantation. Furthermore,
(See figure on previous page.)
Fig. 1 Small molecule-treated MSCs (iMDFECs) change cell type-specific marker expression and gain angiogenic ability in vitro. a Immunocytochemical
monitoring of MSCs treated with SB (1 μM, every 3 days). CD90 and CD31 were used as representative markers of MSCs and ECs, respectively.
Scale bar = 50 μm. Fluorescence intensities are quantified on the upper right side. *P < 0.05. b EC marker gene expression in iMDFECs. mRNA expression
levels of CD34, eNOS, VE-cadherin, VCAM-1, and Flk-1 were measured by using reverse transcription-polymerase chain reaction. GAPDH was
used for normalization. *P < 0.05. c Flk-1 and Ace-α-tubulin expressions in iMDFECs. *P < 0.05. d After 16 days of treatment, iMDFECs were
re-seeded and stimulated with vascular endothelial growth factor (VEGF) (20 nM) for 24 h. The angiogenic ability (tube formation; total tube
length) of iMDFECs was compared with that of control MSCs. Scale bar = 400 μm. *P < 0.05. e Cells were stimulated with 5 μM acetylcholine for
60 min, and the media were collected and subjected to an NO release fluorometric assay. Data represent mean ± standard deviation of at least
three independent experiments. EC endothelial cell, eNOS endothelial nitric oxide synthase, Flk-1 vascular endothelial growth factor receptor 1,
GAPDH glyceraldehyde 3-phosphate dehydrogenase, iMDFEC induced mesenchymal stem cell-derived functional endothelial cell, MSC mesenchymal
stem cell, NO nitric oxide, SB SB216763, VCAM-1 vascular cell adhesion molecule 1, VE-cadherin vascular endothelial cadherin
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neointima formation was significantly inhibited in the
iMDFEC-transplanted group compared with the other
groups on day 21 (34.22±14.09 compared with 136.13
±12.71 for the BI + MSC group and 141±3.37 for the BI-
only group) (Fig. 2c). The neointima thickness of the BI +
iMDFEC group was significantly lower than that of the
other groups from day 7 to 21 (Additional file 9: Figure
S8B). These data together indicate that iMDFECs facili-
tated relatively faster endothelialization of denuded blood
vessels, and this change, in turn, suppressed neointima
Fig. 2 Transplantation of iMDFECs after vascular injury significantly inhibited neointima formation and achieved rapid endothelialization of denuded
vessels in vivo. a Tracking transplanted iMDFECs by using Y chromosome staining (fluorescence in situ hybridization). Left scale bar = 12.5 μm. Right
scale bar = 50 μm. b Representative images of an Evans Blue-stained carotid artery showing transmural coverage (upper panels) and a
cross-section of a hematoxylin-and-eosin-stained carotid artery to show neointima formation (bottom panels). More blue indicates increased
permeability. Scale bar = 200 μm. c Time-dependent changes in transluminal coverage were plotted against neointima thickness (n = 3). See
Additional file 9: Figure S8 for statistical significance. DAPI 4ʹ,6-diamidino-2-phenylindole, iMDFEC induced mesenchymal stem cell-derived
functional endothelial cell, MSC mesenchymal stem cell, SMC smooth muscle cell
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formation, recapitulating the role of a functional endothe-
lial layer in preventing aberrant outgrowth of underlying
VSMCs [27].
Closer examination using a scanning electron micro-
scope indicated that the morphology of the innermost
layer of the carotid artery of iMDFEC-transplanted ani-
mals resembled that of a control, uninjured endothelium
but that the innermost layer of the carotid artery from
the MSC-transplanted animals showed a less dense
organization of cells with relatively bigger gaps between
cells (Fig. 3a). Bone marrow-derived endothelial-like
cells are capable of vasorelaxation in response to ACh
treatment [28, 29]. We also examined the ACh-induced
vasorelaxation of carotid arteries from iMDFEC-
transplanted animals. Our data indicate that the vasore-
laxation of carotid arteries of the iMDFEC-transplanted
group was substantially higher than that of the control
MSC-transplanted group (43.42±4.46 vs. 27.10±4.06),
and this value was comparable to that of normal carotid
arteries (Fig. 3b). Furthermore, the iMDFEC-infused
group had the highest flow rate (3.89±0.22 ml/min)
compared with that of both the sham group (1.40±0.09
ml/min) and the control MSC-infused group (2.22±0.10
ml/min) (Fig. 3c). Taken together, these data indicate
that the carotid artery from the animals that received
iMDFEC infusion was functionally comparable to that of
a normal carotid artery and was much improved com-
pared with that from the animals that received MSC
infusion.
SB is a GSK3β inhibitor [30], and GSK3β is known to
inhibit the Wnt/β-catenin signaling pathway by facilitat-
ing phosphorylation of β-catenin at Ser33, Ser37, and
Fig. 3 The morphology and function of the iMDFEC-transplanted carotid artery have greater similarity to those of intact blood vessels compared
with those of the MSC-transplanted carotid artery. a The innermost layer of explanted carotid arteries was examined by using a scanning electron
microscope. b Relaxation profiles of acetylcholine-stimulated carotid artery segments. The acetylcholine-induced relaxation responses are expressed as
the percentage of the maximal contractions in response to 50 K+ solution. *P < 0.05. c Blood flow was measured for each group. *P < 0.05 compared
with the control. G-MSC gingival mesenchymal stem cell, iMDFEC induced mesenchymal stem cell-derived functional endothelial cell, MSC mesenchymal
stem cell
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Thr41 [31]; this phosphorylation initiates ubiquitination
and proteasomal degradation of cytoplasmic β-catenin
[32]. In fact, a GSK3β inhibitor has been reported to
promote activation of the Wnt/β-catenin signaling path-
way [33]. Our results also indicate that SB treatment
increased the phosphorylation of GSK3β at Ser9 (Add-
itional file 10: Figure S9A), which is known to inactivate
GSK3β [34], and increased the nuclear localization of β-
catenin (Additional file 10: Figure S9B). Nevertheless,
the EC differentiation-inducing ability of SB may not be
due primarily to its inhibitory action on GSK3β under
our experimental conditions because 3 l additional
GSK3β inhibitors with comparable IC50 (half maximal
inhibitory concentration) values (TWS119, kenpaullone,
and indirubin-3′-oxime) [35] showed far inferior po-
tency to induce CD31 expression in MSCs compared
with that of SB (Additional file 10: Figure S9C). In other
words, the EC differentiation potency of SB may stem
from its core structure rather than from its inhibitory ef-
fect on GSK3β.
To test this assumption, first, we selected two core
structures from SB, 1H-pyrrole-2,5-dione and 1H-indole,
that are expected to exhibit a wide range of biological
activities. Based on these structures, we searched com-
mercially available compounds with no confirmed
GSK3β inhibitory effects (11 derivatives with a 1H-
Fig. 4 SB derivatives tested for induction of endothelial cell markers in mesenchymal stem cells. a Derivatives with a 1H-pyrrole-2,5-dione moiety.
b Derivatives with a 1H-indole moiety. The number of plus signs indicates the number visible polymerase chain reaction bands detected from
three independent sets. Minus signs indicate no visible band detected. SB SB216763, VCAM-1 vascular cell adhesion molecule 1, vWF von
Willebrand factor
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pyrrole-2,5-dione moiety and three derivatives with a
1H-indole moiety as the core structure, Additional file
11: Figure S10), and we screened these 14 SB derivatives
for their EC differentiation potency by examining the
expression levels of the EC markers CD31, vWF, and
VCAM-1 after 9 days of treatment.
The results of RT-PCR screening indicated that five of
11 derivatives with a 1H-pyrrole-2,5-dione structure in-
duced the expression of all three EC markers at least
once in three independent differentiation tests but that
one of three derivatives with a 1H-indole structure did
so (Fig. 4), indicating that the 1H-pyrrole-2,5-dione
structure may be important for the EC differentiating
capability of those derivatives. We are currently trying to
verify the speculated EC differentiation-inducing effect
of 1H-pyrrole-2,5-dione and to investigate the possible
underlying mechanisms, such as transcription factor
regulation, of the 1H-pyrrole-2,5-dione effect on EC dif-
ferentiation. We also plan to synthesize a new series of
1H-pyrrole-2,5-dione derivatives to optimize and im-
prove the activity and efficiency of EC differentiation
without undesirable effects.
Previous studies have reported the EC differentiation
of MSCs by using various methods, including a combin-
ation of a mechanical stimulus, such as shear stress, and
VEGF [36], plating cell density [37], and the addition of
extracellular matrix [17]. Furthermore, more recent
studies used small molecules to induce EC differenti-
ation [38, 39]. We also used small molecules to induce
the EC differentiation of MSCs, demonstrating that
small molecules may be used to induce the EC differen-
tiation of stem cells. Although most of the previous
studies focused on an in vitro characterization of the dif-
ferentiated cells, we conducted in vivo experiments by
using an animal model to examine the functions of dif-
ferentiated cells. The results of our study demonstrate
that the iMDFECs generated by using the identified
small molecules are effective in rapid repairing of injured
blood vessels in vivo.
Conclusions
In the present study, we conducted PCA by using the
results from cell-based chemical screening to identify a
small-molecule inducer of the EC differentiation of
MSCs and demonstrated that 1H-pyrrole-2,5-dione-
based small molecules may promote the EC differenti-
ation of MSCs. Our data indicated that the resulting
iMDFECs possessed characteristics of ECs in vitro and
in vivo. More significantly, compared with control
MSCs, iMDFECs achieved more rapid endothelialization
of denuded blood vessels. This iMDFEC-mediated rapid
endothelialization was associated with significant inhib-
ition of neointima formation after vascular injury in
animals. In addition, the carotid artery of the iMDFEC-
infused animals showed much improved functionality,
such as blood vessel relaxation and blood flow rate,
compared with that of control MSC-infused animals.
Taken together, the results show that 1H-pyrrole-2,5-
dione-based small molecules are potent inducers of
MDFECs that can further improve the outcomes of
current interventional approaches for managing vascular
diseases, such as restenosis and atherosclerosis.
Additional files
Additional file 1: Figure S1. Differentiation potential of rat MSCs
isolated by using an in-house protocol. (A) Osteogenic differentiation of
MSCs was detected by immunocytochemistry by using anti-osteocalcin
antibodies. (B) Adipogenic differentiation of MSCs was detected by
immunocytochemistry by using anti-FABP4 (fatty acid-binding protein 4)
antibodies. (C) Chondrogenic differentiation of MSCs was detected by
immunocytochemistry by using anti-aggrecan antibodies. MSC
mesenchymal stem cell. (TIFF 418 kb)
Additional file 2: Table S1. Primers for reverse transcription-polymerase
chain reaction. (TIFF 62 kb)
Additional file 3: Figure S2. Principal component analysis (PCA)
suggests that the small molecule KI-7 will induce the EC differentiation of
MSCs. The PCA results showing a cross-relationship between specific cell
types and the screened small molecules (yellow balls). Chemical names
with targets in parenthesis: KI-0: no inhibitor; KI-1: lavendustin (5-(N-2,5-
dihydroxybenzyl) aminosalicylic acid (CaMKII); KI-2:(4-(4-(2,3-dihydrobenzo
[1, 4] dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide (CKI); KI-3:
6-cyclohexylmethoxy-2-(4-sulfamoylanilino) purine (CDK1,2); KI-4: 3-(pyridin-
2-yl)-4-(4-quinonyl)]-1Hpyrazole (TGFβRI kinase); KI-5: N-[2-((p-bromocinnamyl)
amino)ethyl]-5-isoquinolinesulfonamide, 2HCl (PKA); KI-6: (2-[1-(3-
dimethylaminopropyl)-5-methoxyindol-3-yl]-3-(1H-indol-3-yl)) maleimide
(PKC); KI-7: 3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,
5-dione (GSK3β); KI-8: 4-[(3-bromophenyl) amino]-6,7-diethoxyquinazoline
(PTK); KI-9: N- (4-pyridyl)-N-(2,4,6-trichlorophenyl) urea (ROCK); KI-10: 4,
5-dimethoxy-2-nitrobenzaldehyde (DNA-PK); KI-11: 4-(4-fluorophenyl)-2-(4-
hydroxyphenyl)-5-(4-pyridyl)1H-imidazole (p38 MAPK). CaMK calcium/
calmodulin-dependent protein kinase; CDK cyclin-dependent kinase, CK
casein kinase I, DNA-PK DNA-dependent protein kinase, GSK glycogen
synthase kinase, KI kinase inhibitor, MAPK mitogen-activated protein kinase,
MSC mesenchymal stem cell, PC principal component, PKA protein
kinase A, PKC protein kinase C, PTK protein tyrosine kinase, ROCK
rho-associated protein kinase, TGFβ RI transforming growth factor beta
type I receptor. (TIFF 91 kb)
Additional file 4: Figure S3. EC marker expression in iMDFECs. MSCs
treated with SB for 16 days to induce EC differentiation. (A) CD34 expression
was measured by immunocytochemistry by using anti-CD34 antibodies. (B)
vWF expression was measured by immunocytochemistry by using anti-vWF
antibodies. EC endothelial cell, iMDFEC induced mesenchymal stem
cell-derived functional endothelial cell, MSC mesenchymal stem cell,
SB SB216763, vWF von Willebrand factor. (TIFF 269 kb)
Additional file 5: Figure S4. Time-dependent changes of iMDFECs. (A)
Morphological examination of iMDFECs at indicated time points. (B) The
mRNA expression levels of the MSC marker CD71 and the EC marker
CD31 were examined at the indicated time points. Data represent the
mean ± standard deviation of at least three independent experiments. EC
endothelial cell, iMDFEC induced mesenchymal stem cell-derived functional
endothelial cell, MSC mesenchymal stem cell. (TIFF 270 kb)
Additional file 6: Figure S5. Lipid uptake assay using DiI-LDL. MSCs or
iMDFECs were incubated with DiI-LDL (10 μg/ml) for 4 h. The cells were
lysed in 0.1 N NaOH and 0.1 % SDS, and the amount of DiI-LDL was
determined by fluorescence reading (excitation/emission at 530/580 nm).
The fluorescence of DiI-LDL was normalized by the cell lysate protein
concentrations. DiI-LDL 3,3′-dioctadecylindocarbocyanine-low density
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lipoprotein, iMDFEC induced mesenchymal stem cell-derived functional
endothelial cell, MSC mesenchymal stem cell. (TIFF 33 kb)
Additional file 7: Figure S6. Evaluation of amount of MSCs or iMDFECs
incorporated by using SRY as a marker of incorporated male-origin
transplanted cells. Total RNA was prepared from the common carotid artery
harvested at day 21 after the balloon injury. Data represent the
mean ± standard deviation of three independent experiments.
iMDFEC induced mesenchymal stem cell-derived functional
endothelial cell, MSC mesenchymal stem cell. (TIFF 114 kb)
Additional file 8: Figure S7. Time-dependent changes in vessel
permeability and neointima thickness after transplantation of MSCs/MDFECs
in balloon-injured animals. (A) Images of an Evans Blue-stained carotid
artery showing transmural coverage. More blue indicates increased
permeability. (B) Images of neointima formation at different time points.
Scale bar = 200 μm. MDFEC mesenchymal stem cell-derived functional
endothelial cell, MSC mesenchymal stem cell. (TIFF 369 kb)
Additional file 9: Figure S8. Quantification of time-dependent changes
in neointima thickness and vessel permeability after transplantation of
MSCs/iMDFECs in balloon-injured animals. (A) Time-dependent changes
in the Evans Blue-impermeable area after balloon injury were measured.
(B) Time-dependent changes in the neointima thickness after balloon
injury were evaluated. *P < 0.05. iMDFEC induced mesenchymal
stem cell-derived functional endothelial cell, MSC mesenchymal stem cell.
(TIFF 73 kb)
Additional file 10: Figure S9. Effect of SB on β-catenin activation and
EC differentiation and efficacy of different GSK3β inhibitors. (A) The
expression levels of phosphorylated GSK3β (pser9GSK3β) and β-catenin
(pβ-catenin) and (B) the nuclear localization of β-catenin were examined
after MSCs were treated with 1 μM SB216763 for 24 h. Scale bar = 50 μm.
White arrows indicate nuclear translocated β-catenin. (C) Effect of different
GSK3β inhibitors (TWS119, kenpaullone, and indirubin-3′-oxime) on the
CD31 induction of MSCs. MSCs were treated with different GSK3β inhibitors
with varying concentrations (0.1, 0.5, and 1 μM) for 16 days, and the expression
of CD31 was examined. EC endothelial cell, GSK3β glycogen synthase kinase
3 beta, MSC mesenchymal stem cell, SB SB216763. (TIFF 112 kb)
Additional file 11: Figure S10. 1H-pyrrole-2,5-dione moiety is
important to induce EC-like differentiation of MSCs. Screening of
SB216763 derivatives for inducing EC marker expressions was conducted.
To examine the potency of SB216763 derivatives for inducing EC
differentiation of MSCs, the MSCs were treated 1 μM of each derivatives for
9 days (media containing corresponding small molecules were changed
every 3 days), and the expressions of EC markers CD31, VCAM1, and vWF
were examined by reverse transcription-polymerase chain reaction. Samples
were collected at 9 days after the initial treatment. EC endothelial cell, MSC
mesenchymal stem cell, VCAM-1 vascular cell adhesion molecule 1, vWF von
Willebrand factor. (TIFF 155 kb)
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